Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Adebrelimab
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Fudan UniversityP2CCC (53)
Adebrelimab
Metastatic Prostate Carcinoma
Fudan UniversityP2CCC (53)
ag-120
CRC
Fudan UniversityP2CCC (53)
ag-120
MSS
Fudan UniversityP2CCC (53)
ak131
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Alpha Tocopherol
Colorectal Carcinoma
Fudan UniversityP2CCC (53)
AMINO ACIDS, BRANCHED-CHAIN
Hepatocellular Carcinoma
Fudan UniversityP2CCC (53)
Anti-EGFR Antibody-drug Conjugate MRG003
Hepatocellular Carcinoma
Fudan UniversityP2CCC (53)
b1: trop2 adc
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Benmelstobart
Breast Neoplasm
Fudan UniversityP2CCC (53)
Benmelstobart
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Benmelstobart
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
bp102
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Calcium folinate pentahydrate
ctDNA
Fudan UniversityP2CCC (53)
Capecitabine
ctDNA
Fudan UniversityP2CCC (53)
Capecitabine
Moderately Hypofractionated Radiotherapy
Fudan UniversityP2CCC (53)
Capecitabine
pMMR/MSS
Fudan UniversityP2CCC (53)
Capecitabine
Serplulimab
Fudan UniversityP2CCC (53)
Carboplatin
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Carboplatin
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Carboplatin
HR+HER2- Breast Cancer
Fudan UniversityP2CCC (53)
Carboplatin
Perioperative Immunotherapy
Fudan UniversityP2CCC (53)
Catequentinib
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Catequentinib
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Catequentinib
Clear Cell Renal Carcinoma
Fudan UniversityP2CCC (53)
Showing 201 to 225 of 615 assets
PreviousPage 9 of 25Next